Jade Biosciences (JBIO)

• Market cap: $1.02B
• 1 day: -0.3%
• 5 days: 5.92%
• 1 month: -23.58%
• 3 months: 22.06%
• 6 months: 1.57%
• Year to date: 18.79%
• 1 year: 78.75%
• 5 years: -97.9%
• 10 years: -97.9%
• Sector: Healthcare
• Industry: Biotechnology

About: Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.

Employees: 55